je.st
news
MSD Animal Health Receives Marketing Authorization from European Commission for BRAVECTO (fluralaner)
2014-02-17 09:00:00| Merck.com - Corporate News
Dateline City: SUMMIT, N.J. First Chewable Tablet Approved for Fleas and Ticks in Dogs Effective for 12 Weeks (8 Weeks for Rhipicephalus sanguineus Ticks) SUMMIT, N.J.--(BUSINESS WIRE)--MSD Animal Health, known as Merck Animal Health in the United States and Canada, announced today that following a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Commission has granted marketing authorization for the veterinary medicinal product BRAVECTO (fluralaner) chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg). Language: English Contact: Media:MSD Animal HealthAmy Firsching, +1 908-473-6357orPam Eisele, +1 908-423-5042 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: health
marketing
european
animal
Category:Biotechnology and Pharmaceuticals